Christian Schade most recently served as President and Chief Executive Officer of Halda Therapeutics, a company developing a novel class of cancer therapeutics, until its $3.05 billion acquisition by Johnson & Johnson in December 2025. Prior to Halda, Chris was a Growth Partner at Flagship Pioneering. His leadership experience includes serving as President, Chief Executive Officer and Board Member of Aprea Therapeutics (Nasdaq: APRE) from 2016 to 2022, and as Chairman from 2020 to 2023. Under his leadership, Aprea advanced its pipeline of oncology therapeutics and completed its IPO in 2019. Before joining Aprea, he held several executive roles at biotechnology companies, including: Chief Executive Officer of Novira, a privately held antiviral drug discovery company until its acquisition by Johnson & Johnson, Chief Financial Officer of Omthera Pharmaceuticals, Inc., a Nasdaq-listed specialty pharmaceuticals company until its acquisition by AstraZeneca Plc, and Senior Vice President of Administration and Chief Financial Officer at Medarex, Inc., a biopharmaceutical company focused on antibody-based therapeutics until its acquisition by Bristol Myers Squibb.

Earlier in his career, Mr. Schade was Managing Director at Merrill Lynch in London, following nearly 20 years in corporate finance and capital markets roles at Merrill Lynch and J.P. Morgan in New York and London. Chris received his A.B. degree from Princeton University and an M.B.A. from the Wharton School at the University of Pennsylvania. He currently serves as Senior Advisor to Frazier Life Sciences and is on the Board of Integra LifeSciences.